

## Package leaflet: Information for the user

### Apixaban Teva 5 mg, filmomhulde tabletten apixaban

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### What is in this leaflet

1. What <Invented name> is and what it is used for
2. What you need to know before you take <Invented name>
3. How to take <Invented name>
4. Possible side effects
5. How to store <Invented name>
6. Contents of the pack and other information

#### 1. What <Invented name> is and what it is used for

<Invented name> contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.

<Invented name> is used in adults:

- to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.
- to treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

#### 2. What you need to know before you take <Invented name>

##### Do not take <Invented name> if:

- you are **allergic** to apixaban or any of the other ingredients of this medicine (listed in section 6),
- you are **bleeding excessively**,
- you have a **disease in an organ** of the body that increases the risk of serious bleeding (such as **an active or a recent ulcer** of your stomach or bowel, **recent bleeding in your brain**),
- you have a **liver disease** which leads to increased risk of bleeding (hepatic coagulopathy),
- you are **taking medicines to prevent blood clotting** (e.g., warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open, or if a tube is inserted into your blood vessel (catheter ablation) to treat an irregular heartbeat (arrhythmia).

#### Warnings and precautions

Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:

- an **increased risk of bleeding**, such as:
  - **bleeding disorders**, including conditions resulting in reduced platelet activity
  - very **high blood pressure**, not controlled by medical treatment
  - you are older than 75 years
  - you weigh 60 kg or less
- a **severe kidney disease or if you are on dialysis**,
- a **liver problem or a history of liver problems**, <Invented name> will be used with caution in patients with signs of altered liver function
- if you have a **prosthetic heart valve**,
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned.

Take special care with <Invented name>

- if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.

If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. If you are not sure whether a procedure may cause bleeding ask your doctor.

### Children and adolescents

<Invented name> is not recommended in children and adolescents under 18 years of age.

### Other medicines and <Invented name>

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

Some medicines may increase the effects of <Invented name> and some may decrease its effects. Your doctor will decide, if you should be treated with <Invented name> when taking these medicines and how closely you should be monitored.

The following medicines may increase the effects of <Invented name> and increase the chance for unwanted bleeding:

- some **medicines for fungal infections** (e.g. ketoconazole, etc.),
- some **antiviral medicines for HIV/AIDS** (e.g. ritonavir),
- other **medicines that are used to reduce blood clotting** (e.g. enoxaparin, etc.),
- **anti-inflammatory or pain medicines** (e.g. acetylsalicylic acid or naproxen). Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding.
- **medicines for high blood pressure or heart problems** (e.g. diltiazem),
- **antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin norepinephrine re-uptake inhibitors.**

The following medicines may reduce the ability of <Invented name> to help prevent blood clots from forming:

- **medicines to prevent epilepsy or seizures** (e.g. phenytoin, etc.),
- **St John's Wort** (a herbal supplement used for depression),
- **medicines to treat tuberculosis or other infections** (e.g. rifampicin)

### Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.

The effects of apixaban on pregnancy and the unborn child are not known. You should not take <Invented name> if you are pregnant. **Contact your doctor immediately** if you become pregnant while taking <Invented name>.

It is not known if apixaban passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you either to stop breast-feeding or to stop/not start taking <Invented name>.

### **Driving and using machines**

Apixaban has not been shown to impair your ability to drive or use machines.

### **<Invented name> contains lactose (a type of sugar) and sodium**

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say it is essentially 'sodium-free'.

## **3. How to take <Invented name>**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.

### **Dose**

Swallow the tablet with a drink of water. <Invented name> can be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take <Invented name>. The tablet may be crushed and mixed with water, or 5% dextrose in water, or apple juice or apple puree, immediately before you take it.

### **Instructions for crushing:**

- Crush the tablets with a pestle and mortar.
- Transfer all the powder carefully into a suitable container then mix the powder with a little e.g. 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.
- Swallow the mixture.
- Rinse the pestle and mortar you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g., 30 mL), and swallow the rinse.

If necessary, your doctor may also give you the crushed <Invented name> tablet mixed in 60 mL of water or 5% dextrose in water, through a nasogastric tube.

### **Take <Invented name> as recommended for the following:**

*To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.*

The recommended dose is one **5 mg** tablet twice a day.

The recommended dose is one **2.5 mg** tablet twice a day if:

- you have severely reduced kidney function
- two or more of the following apply to you:
  - your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater),

- you are 80 years old or older,
- your weight is 60 kg or lower.

The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening. Your doctor will decide how long you must continue treatment for.

*To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs*

The recommended dose is **two 5 mg tablets** twice a day for the first 7 days, for example, two in the morning and two in the evening.

After 7 days the recommended dose is **one 5 mg tablet** twice a day, for example, one in the morning and one in the evening.

*For preventing blood clots from re-occurring following completion of 6 months of treatment*

The recommended dose is one **2.5 mg** tablet twice a day for example, one in the morning and one in the evening.

Your doctor will decide how long you must continue treatment for.

***Your doctor might change your anticoagulant treatment as follows:***

- *Changing from <Invented name> to anticoagulant medicines*  
Stop taking <Invented name>. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.
- *Changing from anticoagulant medicines to <Invented name>*  
Stop taking the anticoagulant medicines. Start treatment with <Invented name> at the time you would have had the next dose of anticoagulant medicine, then continue as normal.
- *Changing from treatment with anticoagulant containing vitamin K antagonist (e.g. warfarin) to <Invented name>*  
Stop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to start taking <Invented name>.
- *Changing from <Invented name> to anticoagulant treatment containing vitamin K antagonist (e.g. warfarin).*  
If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take <Invented name> for at least 2 days after your first dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking <Invented name>.

### **Patients undergoing cardioversion**

If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take <Invented name> at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.

### **If you take more <Invented name> than you should**

**Tell your doctor immediately** if you have taken more than the prescribed dose of <Invented name>. Take the medicine pack with you, even if there are no tablets left.

If you take more <Invented name> than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that may reverse anti-factor Xa activity may be required.

### **If you forget to take <Invented name>**

Take the dose as soon as you remember and:

- take the next dose of <Invented name> at the usual time
- then continue as normal

**If you are not sure what to do or have missed more than one dose,** ask your doctor, pharmacist or nurse.

**If you stop taking <Invented name>**

Do NOT stop taking <Invented name> without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common general side effect of apixaban is bleeding which may be potentially life threatening and require immediate medical attention.

*The following side effects are known if you take apixaban to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.*

**Common side effects (may affect up to 1 in 10 people)**

- Bleeding including:
  - in your eyes
  - in your stomach or bowel
  - from your rectum
  - blood in the urine
  - from your nose
  - from your gums
  - bruising and swelling
- Anaemia which may cause tiredness or paleness
- Low blood pressure which may make you feel faint or have a quickened heartbeat.
- Nausea (feeling sick).
- Blood tests may show:
  - an increase in gamma-glutamyltransferase (GGT).

**Uncommon side effects (may affect up to 1 in 100 people)**

- Bleeding:
  - in your brain or in your spinal column
  - in your mouth or blood in your spit when coughing
  - into your abdomen, or from the vagina
  - bright/red blood in the stools
  - bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
  - from a haemorrhoid
  - tests showing blood in the stools or in the urine
- Reduced number of platelets in your blood (which can affect clotting)
- Blood tests may show:
  - abnormal liver function
  - an increase in some liver enzymes
  - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes
- Skin rash
- Itching
- Hair loss

- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.

#### **Rare side effects (may affect up to 1 in 1,000 people)**

- Bleeding:
  - in your lungs or your throat
  - into the space behind your abdominal cavity
  - into a muscle.

*The following side effects are known if you take apixaban to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.*

#### **Common side effects (may affect up to 1 in 10 people)**

- Bleeding including:
  - from your nose
  - from your gums
  - blood in the urine
  - bruising and swelling
  - in your stomach, your bowel, from your rectum
  - in your mouth
  - from the vagina
- Anaemia which may cause tiredness or paleness
- Reduced number of platelets in your blood (which can affect clotting)
- Nausea (feeling sick)
- Skin rash
- Blood tests may show:
  - an increase in gamma-glutamyltransferase (GGT) or alanine aminotransferase (ALT).

#### **Uncommon side effects (may affect up to 1 in 100 people)**

- Low blood pressure which may make you feel faint or have a quickened heartbeat
- Bleeding:
  - in your eyes
  - in your mouth or blood in your spit when coughing
  - bright/red blood in the stools
  - tests showing blood in the stools or in the urine
  - bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site
  - from a haemorrhoid
  - into a muscle
- Itching
- Hair loss
- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms
- Blood tests may show:
  - abnormal liver function
  - an increase in some liver enzymes
  - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.

#### **Rare side effects (may affect up to 1 in 1,000 people)**

- Bleeding:
  - in your brain or in your spinal column
  - in your lungs.

### **Not known (frequency cannot be estimated from the available data)**

- Bleeding:
  - into your abdomen or the space behind your abdominal cavity.

### **Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via **the national reporting system** listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

## **5. How to store <Invented name>**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton, bottle and blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater **or household waste**. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## **6. Contents of the pack and other information**

### **What <Invented name> contains**

- The active substance is apixaban. Each tablet contains 5 mg of apixaban.
- The other ingredients are:
  - Tablet core: lactose (see section 2), microcrystalline cellulose, croscarmellose sodium, sodium laurilsulfate, magnesium stearate.
  - Film-coating: lactose monohydrate (see section 2), hypromellose (E464), titanium dioxide (E171), macrogol 3350, triacetin, red iron oxide (E172).

### **What <Invented name> looks like and contents of the pack**

The tablets are light pink, film-coated, modified oval shape tablet, debossed with “TV” on one side and with “G2” on the other side of the tablet. Dimension: 9.9 – 10.5 mm length, 5.0 – 5.6 mm width, 4.2 – 4.8mm thickness.

<Invented name> comes in

- unit dose blisters of 10 X 1, 14 X 1, 20 X 1, 28 X 1, 30 X 1, 56 X 1, 60 X 1, 100 X 1, 120 X 1, 168 X 1, 200 X 1 film-coated tablets
- tablet containers of 180, 200 and 500 film-coated tablets and
- tablet containers of 180, 200 and 500 film-coated tablets including cotton.

Not all pack sizes may be marketed.

### **Patient Alert Card: handling information**

Inside the <Invented name> pack together with the package leaflet you will find a Patient Alert Card or your doctor might give you a similar card.

This Patient Alert Card includes information that will be helpful to you and alert other doctors that you are taking <Invented name>. **You should keep this card with you at all times.**

1. Take the card
2. Complete the following sections or ask your doctor to do it:
  - Name:
  - Birth Date:
  - Indication:
  - Dose : .....mg twice daily
  - Doctor's Name:
  - Doctor's telephone:
3. Fold the card and keep it with you at all times

**Houder van de vergunning voor het in de handel brengen en fabrikant**

*Houder van de vergunning voor het in de handel brengen*

Teva B.V.  
Swensweg 5  
2031 GA Haarlem  
Nederland

*Fabrikant*

Teva Pharma B.V.  
Swensweg 5  
2031 GA Haarlem  
Nederland

Balkanpharma-Dupnitsa AD  
3 Samokovsko Shosse Str.  
2600 Dupnitsa  
Bulgarije

**In het register ingeschreven onder**

RVG 125129

**Dit geneesmiddel is geregistreerd in lidstaten van de EEA onder de volgende namen:**

België	Apixaban Teva 5 mg filmomhulde tabletten / comprimés pelliculés / Filmtabletten
Bulgarije	Апиксабан Тева 5 мг филмирани таблетки
Denemarken	Apixaban Teva
Duitsland	Apixaban-ratiopharm 5 mg Filmtabletten
Estland	Apixaban Teva
Finland	Apixaban ratiopharm 5 mg tabletti, kalvopäällysteinen
Frankrijk	Apixaban TEVA 5 mg, comprimé pelliculé
Hongarije	Apixaban-Teva 5 mg filmtabletta
Ierland	Apixaban Teva 5 mg Filmcoated Tablets
IJsland	Apixaban Teva
Italië	APIXABAN TEVA
Kroatië	Apiksaban Pliva 5 mg filmom obložene tablete
Letland	Apixaban Teva 5 mg apvalkotās tabletes
Litouwen	Apixaban Teva 5 mg plėvele dengtos tabletės
Luxemburg	Apixaban-ratiopharm 5 mg Filmtabletten
Nederland	Apixaban Teva 5 mg, filmomhulde tabletten
Noorwegen	Apixaban Teva
Oostenrijk	Apixaban ratiopharm 5 mg Filmtabletten
Polen	Apixaban Teva
Roemenië	Apixaban Teva 5 mg comprimate filmate
Slovenië	Apiksaban Teva 5 mg filmsko obložene tablete
Slowakije	Apixaban Teva 5 mg



Spanje	Apixaban Teva 5 mg comprimidos recubiertos con película EFG
Tsjechië	Apixaban Teva
Verenigd Koninkrijk (Noord-Ierland)	Apixaban Teva 5 mg Filmcoated Tablets
Zweden	Apixaban Teva 5mg filmdragerade tabletter

**Deze bijsluiter is voor het laatst goedgekeurd in september 2021.**